{
    "Trade/Device Name(s)": [
        "Optilite Freelite Mx Kappa Free Kit",
        "Optilite Freelite Mx Lambda Free Kit"
    ],
    "Submitter Information": "The Binding Site Group Ltd",
    "510(k) Number": "K173732",
    "Predicate Device Reference 510(k) Number(s)": [
        "K040009"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DFH",
        "DEH"
    ],
    "Summary Letter Date": "July 26, 2018",
    "Summary Letter Received Date": "July 31, 2018",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5550"
    ],
    "Regulation Name(s)": [
        "Immunoglobulin (light chain specific) immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Kappa free light chains",
        "Lambda free light chains"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Binding Site Optilite analyser"
    ],
    "Method(s)/Technology(ies)": [
        "Turbidimetric assay"
    ],
    "Methodologies": [
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Kit",
        "Reagent",
        "Calibrator",
        "Control",
        "Buffer"
    ],
    "Document Summary": "FDA 510(k) summary for Optilite Freelite Mx Kappa and Lambda Free Kits for quantitative measurement of free light chains in serum and urine using turbidimetric assay",
    "Indications for Use Summary": "Quantitative in vitro measurement of kappa and lambda free light chains in serum and urine to aid in diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenstr\u00f6m\u2019s macroglobulinaemia, AL amyloidosis, light chain deposition disease, and connective tissue diseases such as systemic lupus erythematosus (SLE), in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}